249 related articles for article (PubMed ID: 20949350)
1. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.
Akhondzadeh S; Ghayyoumi R; Rezaei F; Salehi B; Modabbernia AH; Maroufi A; Esfandiari GR; Naderi M; Ghebleh F; Tabrizi M; Rezazadeh SA
Psychopharmacology (Berl); 2011 Feb; 213(4):809-15. PubMed ID: 20949350
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
[TBL] [Abstract][Full Text] [Related]
3. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Akhondzadeh S; Malek-Hosseini M; Ghoreishi A; Raznahan M; Rezazadeh SA
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1879-83. PubMed ID: 18801405
[TBL] [Abstract][Full Text] [Related]
4. Re: sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia.
Kaushik GN
Psychopharmacology (Berl); 2011 May; 215(2):401; author reply 399. PubMed ID: 21193982
[No Abstract] [Full Text] [Related]
5. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
[TBL] [Abstract][Full Text] [Related]
6. A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia.
Arbabi M; Bagheri M; Rezaei F; Ahmadi-Abhari SA; Tabrizi M; Khalighi-Sigaroudi F; Akhondzadeh S
Psychopharmacology (Berl); 2012 Apr; 220(3):591-8. PubMed ID: 21947320
[TBL] [Abstract][Full Text] [Related]
7. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
[TBL] [Abstract][Full Text] [Related]
8. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial.
Abbasi SH; Behpournia H; Ghoreshi A; Salehi B; Raznahan M; Rezazadeh SA; Rezaei F; Akhondzadeh S
Schizophr Res; 2010 Feb; 116(2-3):101-6. PubMed ID: 19959338
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia.
Ghaleiha A; Noorbala AA; Farnaghi F; Hajiazim M; Akhondzadeh S
J Clin Psychopharmacol; 2010 Dec; 30(6):678-82. PubMed ID: 21105281
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
[TBL] [Abstract][Full Text] [Related]
11. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
[TBL] [Abstract][Full Text] [Related]
12. Sildenafil citrate in the treatment of pain in primary dysmenorrhea: a randomized controlled trial.
Dmitrovic R; Kunselman AR; Legro RS
Hum Reprod; 2013 Nov; 28(11):2958-65. PubMed ID: 23925396
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.
Akhondzadeh S; Tabatabaee M; Amini H; Ahmadi Abhari SA; Abbasi SH; Behnam B
Schizophr Res; 2007 Feb; 90(1-3):179-85. PubMed ID: 17208413
[TBL] [Abstract][Full Text] [Related]
14. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial.
Moazen-Zadeh E; Bayanati S; Ziafat K; Rezaei F; Mesgarpour B; Akhondzadeh S
J Psychopharmacol; 2020 May; 34(5):506-513. PubMed ID: 32122230
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
Farokhnia M; Sabzabadi M; Pourmahmoud H; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Akhondzadeh S
Psychopharmacology (Berl); 2014 Feb; 231(3):533-42. PubMed ID: 24013610
[TBL] [Abstract][Full Text] [Related]
16. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia.
Noroozian M; Ghasemi S; Hosseini SM; Modabbernia A; Khodaie-Ardakani MR; Mirshafiee O; Farokhnia M; Tajdini M; Rezaei F; Salehi B; Ashrafi M; Yekehtaz H; Tabrizi M; Akhondzadeh S
Psychopharmacology (Berl); 2013 Aug; 228(4):595-602. PubMed ID: 23515583
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia.
Xiao SF; Xue HB; Li X; Chen C; Li GJ; Yuan CM; Zhang MY
Neurosci Bull; 2011 Aug; 27(4):258-68. PubMed ID: 21788997
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S
Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
[TBL] [Abstract][Full Text] [Related]
20. Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial.
Ghanizadeh A; Dehbozorgi S; OmraniSigaroodi M; Rezaei Z
Recent Pat Inflamm Allergy Drug Discov; 2014; 8(3):211-5. PubMed ID: 25353174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
